DE602004025463D1 - Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol - Google Patents

Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol

Info

Publication number
DE602004025463D1
DE602004025463D1 DE602004025463T DE602004025463T DE602004025463D1 DE 602004025463 D1 DE602004025463 D1 DE 602004025463D1 DE 602004025463 T DE602004025463 T DE 602004025463T DE 602004025463 T DE602004025463 T DE 602004025463T DE 602004025463 D1 DE602004025463 D1 DE 602004025463D1
Authority
DE
Germany
Prior art keywords
ciclesonide
formoterol
conservation
fine particle
particle proportion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004025463T
Other languages
English (en)
Inventor
Nicholas Heaton
Zoe Heaton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of DE602004025463D1 publication Critical patent/DE602004025463D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment
DE602004025463T 2003-05-28 2004-05-27 Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol Active DE602004025463D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312148.0A GB0312148D0 (en) 2003-05-28 2003-05-28 Stabilized pharmaceutical products
PCT/GB2004/002249 WO2004105727A2 (en) 2003-05-28 2004-05-27 Stabilized pharmaceutical product

Publications (1)

Publication Number Publication Date
DE602004025463D1 true DE602004025463D1 (de) 2010-03-25

Family

ID=9958829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025463T Active DE602004025463D1 (de) 2003-05-28 2004-05-27 Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol

Country Status (22)

Country Link
US (4) US7736673B2 (de)
EP (1) EP1626913B1 (de)
JP (1) JP5175048B2 (de)
KR (1) KR20060023539A (de)
CN (1) CN1832890A (de)
AR (1) AR047619A1 (de)
AT (1) ATE457163T1 (de)
AU (1) AU2004243223A1 (de)
BR (1) BRPI0410701A (de)
CA (1) CA2527088C (de)
DE (1) DE602004025463D1 (de)
ES (1) ES2340681T3 (de)
GB (1) GB0312148D0 (de)
MA (1) MA27804A1 (de)
MX (1) MXPA05012757A (de)
NO (1) NO20055443L (de)
PL (1) PL1626913T3 (de)
RS (1) RS20050882A (de)
RU (1) RU2337667C2 (de)
TW (1) TW200509989A (de)
WO (1) WO2004105727A2 (de)
ZA (1) ZA200509099B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572217B1 (de) 2002-12-12 2008-08-20 Nycomed GmbH Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US8435497B2 (en) 2003-06-13 2013-05-07 Takeda Gmbh Formoterol of and ciclesonide combination
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
EP1803457A1 (de) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmazeutische Zubereitung, welche Montelukast enthält
SI1976522T2 (sl) * 2005-12-30 2019-11-29 Krka Tovarna Zdravil D D Novo Mesto Farmacevtski sestavek, ki vsebuje montelukast
US20090308772A1 (en) * 2006-03-17 2009-12-17 Abrams William S Moisture-tight primary packaging for a dry powder inhaler
EP2254630A1 (de) * 2008-02-20 2010-12-01 Boehringer Ingelheim International GmbH Pulverinhalatoren
EP2400950B1 (de) 2009-02-26 2019-05-22 Glaxo Group Limited Pharmazeutische formulierungen enthaltend 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
IN2012DN05912A (de) * 2010-01-22 2015-09-18 Bayer Healthcare Llc
US9233788B2 (en) 2010-01-22 2016-01-12 Bayer Healthcare Llc Biosensor desiccant system having enhanced measurement performance
WO2011093814A2 (en) * 2010-01-29 2011-08-04 Mahmut Bilgic A pharmaceutical combination comprising formoterol and ciclesonide
ES2705494T3 (es) 2010-08-31 2019-03-25 Glaxosmithkline Ip Dev Ltd Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
TWI565943B (zh) * 2011-07-22 2017-01-11 拜耳保健公司 具有增進測量性能之生物感測器乾燥劑系統
EP2751562B1 (de) 2011-09-02 2015-09-16 Nestec S.A. Profilierung von signalwegproteinen zur bestimmung der therapeutischen wirksamkeit
WO2013109212A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
KR20130140358A (ko) 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
WO2014122600A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
US11642309B2 (en) * 2017-10-16 2023-05-09 Faes Farma, S.A. Aqueous compositions comprising bilastine and mometasone
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2023117967A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
EP2266548B1 (de) * 1998-11-13 2020-05-20 Jagotec AG Trockenpulver zur inhalation
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) * 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
NZ522672A (en) 2000-05-23 2004-07-30 Glaxo Group Ltd Aerosol container for formulations of salmeterol xinafoate and preparation process thereof
GB0015043D0 (en) * 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002177A0 (fi) 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
NZ532673A (en) 2001-11-17 2008-07-31 Aventis Pharma Ltd Package comprising a medicament, a component that gradually releases a gaseous substance and an adsorbent material
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
JP2004051502A (ja) * 2002-07-17 2004-02-19 Jcr Pharmaceuticals Co Ltd 成長ホルモン含有安定化粉末製剤
EP1572217B1 (de) 2002-12-12 2008-08-20 Nycomed GmbH Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
US20060293293A1 (en) 2003-05-22 2006-12-28 Altana Pharma Ag Salmeterol and ciclesonide combination
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
NZ544159A (en) * 2003-06-06 2009-04-30 Senesco Technologies Inc Inhibition of apoptosis-specific eIF-5A ("eIF-5A1") with antisense oligonucleotides and siRNAs as anti-inflammatory therapeutics
US8435497B2 (en) 2003-06-13 2013-05-07 Takeda Gmbh Formoterol of and ciclesonide combination
GB0315889D0 (en) 2003-07-08 2003-08-13 Aventis Pharma Ltd Stable pharmaceutical products
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
AU2004243223A1 (en) 2004-12-09
ATE457163T1 (de) 2010-02-15
US8163299B2 (en) 2012-04-24
PL1626913T3 (pl) 2010-07-30
EP1626913A2 (de) 2006-02-22
NO20055443L (no) 2005-11-17
RU2337667C2 (ru) 2008-11-10
ES2340681T3 (es) 2010-06-08
JP2007504277A (ja) 2007-03-01
US20100247585A1 (en) 2010-09-30
ZA200509099B (en) 2006-08-30
JP5175048B2 (ja) 2013-04-03
CN1832890A (zh) 2006-09-13
EP1626913B1 (de) 2010-02-10
GB0312148D0 (en) 2003-07-02
AR047619A1 (es) 2006-02-01
RU2005136869A (ru) 2006-06-10
TW200509989A (en) 2005-03-16
US20110308975A1 (en) 2011-12-22
WO2004105727A2 (en) 2004-12-09
US8029811B2 (en) 2011-10-04
KR20060023539A (ko) 2006-03-14
US20060147537A1 (en) 2006-07-06
RS20050882A (en) 2007-12-31
BRPI0410701A (pt) 2006-06-13
US7736673B2 (en) 2010-06-15
CA2527088C (en) 2011-03-01
CA2527088A1 (en) 2004-12-09
US20120247982A1 (en) 2012-10-04
MXPA05012757A (es) 2006-02-13
MA27804A1 (fr) 2006-03-01
US8440210B2 (en) 2013-05-14
WO2004105727A3 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
DE602004025463D1 (de) Verwendung von ciclesonide zur erhaltung des feinen teilchengrössenanteils von formoterol
DE602004012969D1 (de) Phenylacetamide und ihre verwendung als glukokinase-modulatoren
ATE474578T1 (de) Verwendung von flibanserin bei der behandlung von prämenstruellen störungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
DE602004005753D1 (de) Kombinationen von harzzusammensetzungen und verwendungsverfahren dafür
DE602005021506D1 (de) Phosphonat prodrogen von einem analog des 2'-fluorhiv mittel
ATE465712T1 (de) Ultrafeine zusammensetzungen von formoterol
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DE602005022169D1 (de) Polymerisierbare verbindungen und verwendung davon
DE60328517D1 (de) Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung
NO20051281D0 (no) Sammensetning for anrikning av naeringsmidler
DE502005003904D1 (de) Tetrahydrobenzo (d) azepin-2-on derivate und ihre verwendung zur behandlung von kardiovaskulären krankheiten
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE534635T1 (de) N-pyrazinyl-phenylsulfonamide und deren verwendung zur behandlung von durch chemokine vermittelten krankheiten
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
EP1856527A4 (de) Regulatoren für die missfaltung und aggregation von proteinen und verwendungsverfahren dafür
DE602004021738D1 (de) Katalysator und seine Verwendung zur Verbesserung des Fliesspunktes von Kohlenwasserstoffen
DE602006015163D1 (de) Zusammensetzungen zur abgabe von quecksilber und vorrichtung damit
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition